Contact

All Stories

  1. Microsampling Techniques Suitable for Therapeutic Drug Monitoring of Antipsychotics

    Article • Journal of Clinical Psychopharmacology, April 2024, Wolters Kluwer Health

    Prof. dr. Anton J Loonen

  2. Putative role of immune reactions in the mechanism of tardive dyskinesia

    Article • Brain Behavior & Immunity - Health, November 2023, Elsevier

    Prof. dr. Anton J Loonen

  3. The Mechanism of Akathisia - Comments on Wu et al. Eur Neuropsychopharmacol 2023;72:40–49

    Article • European Neuropsychopharmacology, October 2023, Elsevier

    Prof. dr. Anton J Loonen

  4. Comment on Martino et al. “Scales for Antipsychotic‐Associated Movement Disorders: Systematic Review, Critique, and Recommendations”

    Article • Movement Disorders, August 2023, Wiley

    Prof. dr. Anton J Loonen

  5. Role of Neuroglia in the Habenular Connection Hub of the Dorsal Diencephalic Conduction System

    Article • Neuroglia, February 2023, MDPI AG

    Prof. dr. Anton J Loonen

  6. Polymorphisms in the adrenergic neurotransmission pathway impact antidepressant response in depressed patients

    Article • Neuroscience Applied, January 2023, Elsevier

    Prof. dr. Anton J Loonen

  7. Cytokine level in patients with mood disorder, alcohol use disorder and their comorbidity

    Article • The World Journal of Biological Psychiatry, July 2022, Taylor & Francis

    Prof. dr. Anton J Loonen, Prof Nikolay A. Bokhan, Svetlana A Ivanova

  8. The Gender-Specific Association of DRD2 Polymorphism with Metabolic Syndrome in Patients with Schizophrenia

    Article • Genes, July 2022, MDPI AG

    Prof. dr. Anton J Loonen, Prof Nikolay A. Bokhan, Svetlana A Ivanova

  9. Genes of the Glutamatergic System and Tardive Dyskinesia in Patients with Schizophrenia

    Article • Diagnostics, June 2022, MDPI AG

    Prof. dr. Anton J Loonen, Prof Nikolay A. Bokhan, Svetlana A Ivanova

  10. Circuits regulating pleasure and happiness – focus on potential biomarkers for circuitry including the habenuloid complex

    Article • Acta Neuropsychiatrica, May 2022, Cambridge University Press

    Prof. dr. Anton J Loonen, Svetlana A Ivanova

  11. Gene Polymorphisms of Hormonal Regulators of Metabolism in Patients with Schizophrenia with Metabolic Syndrome

    Article • Genes, May 2022, MDPI AG

    Prof. dr. Anton J Loonen, Prof Nikolay A. Bokhan, Svetlana A Ivanova

  12. Population pharmacokinetic model and limited sampling strategy for clozapine using plasma and dried blood spot samples

    Article • Therapeutic Advances in Psychopharmacology, January 2022, SAGE Publications

    Prof. dr. Anton J Loonen

  13. A New Paradigm to Indicate Antidepressant Treatments

    Article • Pharmaceuticals, December 2021, MDPI AG

    Prof. dr. Anton J Loonen, Prof Nikolay A. Bokhan, Svetlana A Ivanova

  14. Beta-Endorphin and Oxytocin in Patients with Alcohol Use Disorder and Comorbid Depression

    Article • Journal of Clinical Medicine, December 2021, MDPI AG

    Prof. dr. Anton J Loonen, Prof Nikolay A. Bokhan, Svetlana A Ivanova

  15. Influence of eight ABCB1 polymorphisms on antidepressant response in a prospective cohort of treatment‐free Russian patients with moderate or severe depression: An explorative psychopharmacological study with naturalistic design

    Article • Human Psychopharmacology Clinical and Experimental, November 2021, Wiley

    Prof. dr. Anton J Loonen, Prof Nikolay A. Bokhan

  16. Association of PIP4K2A Polymorphisms with Alcohol Use Disorder

    Article • Genes, October 2021, MDPI AG

    Prof. dr. Anton J Loonen, Prof Nikolay A. Bokhan, Svetlana A Ivanova

  17. W86. FTO GENE POLYMORPHISMS AND BODY MASS INDEX IN SCHIZOPHRENIA PATIENTS WITH METABOLIC SYNDROME

    Article • European Neuropsychopharmacology, October 2021, Elsevier

    Prof. dr. Anton J Loonen

  18. Study of Early Onset Schizophrenia: Associations of GRIN2A and GRIN2B Polymorphisms

    Article • Life, September 2021, MDPI AG

    Prof. dr. Anton J Loonen, Prof Nikolay A. Bokhan, Svetlana A Ivanova

  19. Search for Possible Associations of FTO Gene Polymorphic Variants with Metabolic Syndrome, Obesity and Body Mass Index in Schizophrenia Patients

    Article • Pharmacogenomics and Personalized Medicine, September 2021, Taylor & Francis

    Prof. dr. Anton J Loonen, Prof Nikolay A. Bokhan

  20. Clinical Evaluation of Different Treatment Strategies for Motor Recovery in Poststroke Rehabilitation during the First 90 Days

    Article • Journal of Clinical Medicine, August 2021, MDPI AG

    Prof. dr. Anton J Loonen, Svetlana A Ivanova

  21. Preliminary Pharmacogenetic Study to Explore Putative Dopaminergic Mechanisms of Antidepressant Action

    Article • Journal of Personalized Medicine, July 2021, MDPI AG

    Prof. dr. Anton J Loonen, Prof Nikolay A. Bokhan, Svetlana A Ivanova

  22. Comparative Characteristics of the Metabolic Syndrome Prevalence in Patients With Schizophrenia in Three Western Siberia Psychiatric Hospitals

    Article • Frontiers in Psychiatry, July 2021, Frontiers

    Prof. dr. Anton J Loonen, Prof Nikolay A. Bokhan

  23. Cytokine Level Changes in Schizophrenia Patients with and without Metabolic Syndrome Treated with Atypical Antipsychotics

    Article • Pharmaceuticals, May 2021, MDPI AG

    Prof. dr. Anton J Loonen, Prof Nikolay A. Bokhan, Svetlana A Ivanova

  24. Genetic Polymorphisms of 5-HT Receptors and Antipsychotic-Induced Metabolic Dysfunction in Patients with Schizophrenia

    Article • Journal of Personalized Medicine, March 2021, MDPI AG

    Prof. dr. Anton J Loonen, Prof Nikolay A. Bokhan, Svetlana A Ivanova

  25. Putative role of vitamin D in the mechanism of alcoholism and other addictions – a hypothesis

    Article • Acta Neuropsychiatrica, November 2020, Cambridge University Press

    Prof. dr. Anton J Loonen

  26. P.541 Inflammation in schizophrenia with metabolic syndrome: features of the cytokine spectrum

    Article • European Neuropsychopharmacology, November 2020, Elsevier

    Prof. dr. Anton J Loonen, Prof Nikolay A. Bokhan

  27. P.143 Population pharmacokinetic model and limited sampling strategy for clozapine using plasma and dried blood spot samples

    Article • European Neuropsychopharmacology, November 2020, Elsevier

    Prof. dr. Anton J Loonen

  28. P.583 Polymorphisms in BDNF, AKT1, GSK3B genes: possible association with antipsychotic-induced hyperprolactinemia in schizophrenia patients

    Article • European Neuropsychopharmacology, November 2020, Elsevier

    Prof. dr. Anton J Loonen, Prof Nikolay A. Bokhan

  29. Adipocytokines and Metabolic Syndrome in Patients with Schizophrenia

    Article • Metabolites, October 2020, MDPI AG

    Prof. dr. Anton J Loonen, Prof Nikolay A. Bokhan, Svetlana A Ivanova

  30. Genetic polymorphisms of PIP5K2A and course of schizophrenia

    Article • BMC Medical Genetics, October 2020, Springer Science + Business Media

    Prof. dr. Anton J Loonen, Prof Nikolay A. Bokhan

  31. Body Fat Parameters, Glucose and Lipid Profiles, and Thyroid Hormone Levels in Schizophrenia Patients with or without Metabolic Syndrome

    Article • Diagnostics, September 2020, MDPI AG

    Prof. dr. Anton J Loonen, Prof Nikolay A. Bokhan, Svetlana A Ivanova, Dr Olga Lobacheva

  32. Neurobiological mechanisms associated with antipsychotic drug-induced dystonia

    Article • Journal of Psychopharmacology, September 2020, SAGE Publications

    Prof. dr. Anton J Loonen

  33. Serum BDNF’s Role as a Biomarker for Motor Training in the Context of AR-Based Rehabilitation after Ischemic Stroke

    Article • Brain Sciences, September 2020, MDPI AG

    Prof. dr. Anton J Loonen, Svetlana A Ivanova

  34. COMT gene polymorphism and antipsychotic- induced hyperprolactinemia in schizophrenia patients

    Article • July 2020, Institute of Electrical & Electronics Engineers (IEEE)

    Prof. dr. Anton J Loonen

  35. Association of ANKK1 polymorphism with antipsychotic‐induced hyperprolactinemia

    Article • Human Psychopharmacology Clinical and Experimental, May 2020, Wiley

    Prof Nikolay A. Bokhan, Prof. dr. Anton J Loonen, Svetlana A Ivanova

  36. 5-Hydroxytryptamine Receptors and Tardive Dyskinesia in Schizophrenia

    Article • Frontiers in Molecular Neuroscience, April 2020, Frontiers

    Prof. dr. Anton J Loonen, Prof Nikolay A. Bokhan

  37. Exploring Brain Derived Neurotrophic Factor and Cell Adhesion Molecules as Biomarkers for the Transdiagnostic Symptom Anhedonia in Alcohol Use Disorder and Comorbid Depression

    Article • Frontiers in Psychiatry, April 2020, Frontiers

    Prof. dr. Anton J Loonen, Prof Nikolay A. Bokhan

  38. Association between 8 P-glycoprotein (MDR1/ABCB1) gene polymorphisms and antipsychotic drug-induced hyperprolactinaemia

    Article • British Journal of Clinical Pharmacology, April 2020, Wiley

    Prof Nikolay A. Bokhan, Prof. dr. Anton J Loonen

  39. Association of Cholinergic Muscarinic M4 Receptor Gene Polymorphism with Schizophrenia

    Article • The Application of Clinical Genetics, April 2020, Taylor & Francis

    Prof Nikolay A. Bokhan, Prof. dr. Anton J Loonen

  40. Cortisol and DHEAS Related to Metabolic Syndrome in Patients with Schizophrenia

    Article • April 2020, Taylor & Francis

    Prof Nikolay A. Bokhan, Prof. dr. Anton J Loonen, Svetlana A Ivanova

  41. Association Between BDNF Gene Variant Rs6265 and the Severity of Depression in Antidepressant Treatment-Free Depressed Patients

    Article • Frontiers in Psychiatry, February 2020, Frontiers

    Prof Nikolay A. Bokhan, Prof. dr. Anton J Loonen, Svetlana A Ivanova

  42. Abstracts of the 86th Annual Meeting of the German Society for Experimental and Clinical Pharmacology and Toxicology (DGPT) With contribution of the Arbeitsgemeinschaft für Angewandte Humanpharmakologie e. V. (AGAH)

    Article • Naunyn-Schmiedeberg s Archives of Pharmacology, February 2020, Springer Science + Business Media

    Prof. dr. Anton J Loonen

  43. Diagnose, indicate, and treat severe mental illness (DITSMI) as appropriate care: A three-year follow-up study in long-term residential psychiatric patients on the effects of re-diagnosis on medication prescription, patient functioning, and hospital be...

    Article • European Psychiatry, January 2020, Royal College of Psychiatrists

    Prof. dr. Anton J Loonen

  44. Limited Associations Between 5-HT Receptor Gene Polymorphisms and Treatment Response in Antidepressant Treatment-Free Patients With Depression

    Article • Frontiers in Pharmacology, December 2019, Frontiers

    Prof. dr. Anton J Loonen, Prof Nikolay A. Bokhan, Svetlana A Ivanova

  45. Investigating the potential role of BDNF and PRL genotypes on antidepressant response in depression patients: A prospective inception cohort study in treatment-free patients

    Article • Journal of Affective Disorders, December 2019, Elsevier

    Prof Nikolay A. Bokhan, Prof. dr. Anton J Loonen, Svetlana A Ivanova

  46. P.374 Cortisol and DHEAS related to metabolic side effects in patients with schizophrenia

    Article • European Neuropsychopharmacology, December 2019, Elsevier

    Prof. dr. Anton J Loonen

  47. P.390 Characteristics of metabolic hormones in patients with schizophrenia with antipsychotic-induced metabolic syndrome

    Article • European Neuropsychopharmacology, December 2019, Elsevier

    Prof. dr. Anton J Loonen, Prof Nikolay A. Bokhan

  48. P.505 The potential role of BDNF and prolactin genotypes on antidepressant response in depressive patients

    Article • European Neuropsychopharmacology, December 2019, Elsevier

    Prof. dr. Anton J Loonen, Prof Nikolay A. Bokhan

  49. Changes in Body Fat and Related Biochemical Parameters Associated With Atypical Antipsychotic Drug Treatment in Schizophrenia Patients With or Without Metabolic Syndrome

    Article • Frontiers in Psychiatry, November 2019, Frontiers

    Prof Nikolay A. Bokhan, Prof. dr. Anton J Loonen, Svetlana A Ivanova

  50. Putative role of pharmacogenetics to elucidate the mechanism of tardive dyskinesia in schizophrenia

    Article • Pharmacogenomics, November 2019, Future Medicine

    Prof. dr. Anton J Loonen, Svetlana A Ivanova

  51. Apolipoprotein serum levels related to metabolic syndrome in patients with schizophrenia

    Article • Heliyon, July 2019, Elsevier

    Prof Nikolay A. Bokhan, Prof. dr. Anton J Loonen, Svetlana A Ivanova

  52. A pharmacogenetic study of patients with schizophrenia from West Siberia gets insight into dopaminergic mechanisms of antipsychotic-induced hyperprolactinemia

    Article • BMC Medical Genetics, April 2019, Springer Science + Business Media

    Prof Nikolay A. Bokhan, Prof. dr. Anton J Loonen, Svetlana A Ivanova

  53. Consider Role of Glutamatergic Habenula-projecting Globus Pallidus in OCD

    Article • Pharmacopsychiatry, February 2019, Thieme Publishing Group

    Prof. dr. Anton J Loonen, Svetlana A Ivanova

  54. Pharmacogenetics of tardive dyskinesia in schizophrenia: The role of CHRM1 and CHRM2 muscarinic receptors

    Article • The World Journal of Biological Psychiatry, January 2019, Taylor & Francis

    Svetlana A Ivanova, Prof. dr. Anton J Loonen, Prof Nikolay A. Bokhan

  55. No evidence so far of a major role of AKT1 and GSK3B in the pathogenesis of antipsychotic-induced tardive dyskinesia

    Article • Human Psychopharmacology Clinical and Experimental, January 2019, Wiley

    Prof Nikolay A. Bokhan, Prof. dr. Anton J Loonen, Svetlana A Ivanova

  56. Apolipoprotein serum levels related to metabolic side effects in patients with schizophrenia

    Article • European Neuropsychopharmacology, January 2019, Elsevier

    Prof. dr. Anton J Loonen, Prof Nikolay A. Bokhan

  57. Genes of neurotrophic factors and responsiveness to antidepressive psychopharmacotherapy in patients with depressive disorders

    Article • European Neuropsychopharmacology, January 2019, Elsevier

    Prof. dr. Anton J Loonen, Prof Nikolay A. Bokhan

  58. Tardive dyskinesia in schizophrenia: Gene polymorphisms of muscarinic and adrenergic receptors

    Article • European Neuropsychopharmacology, January 2019, Elsevier

    Prof. dr. Anton J Loonen

  59. The risk prediction of development of neuroleptic hyperprolactinemia based on genetic markers

    Article • European Neuropsychopharmacology, January 2019, Elsevier

    Prof. dr. Anton J Loonen

  60. The study of dopamine receptor genes in patients with schizophrenia

    Article • European Neuropsychopharmacology, January 2019, Elsevier

    Prof. dr. Anton J Loonen

  61. The evolutionary old forebrain as site of action to develop new psychotropic drugs

    Article • Journal of Psychopharmacology, September 2018, SAGE Publications

    Prof. dr. Anton J Loonen, Svetlana A Ivanova

  62. Polymorphisms of Catechol-O-Methyl Transferase (COMT) Gene in Vulnerability to Levodopa-Induced Dyskinesia

    Article • Journal of Pharmacy & Pharmaceutical Sciences, August 2018, University of Alberta Libraries

    Prof Nikolay A. Bokhan, Prof. dr. Anton J Loonen, Svetlana A Ivanova

  63. Remaining Need for In Vitro Test to Elucidate 5-Hydroxytryptamine 2C Receptor Functioning

    Article • Journal of Clinical Psychopharmacology, August 2018, Wolters Kluwer Health

    Prof Nikolay A. Bokhan, Prof. dr. Anton J Loonen, Svetlana A Ivanova

  64. The functional variant rs334558 of GSK3B is associated with remission in patients with depressive disorders

    Article • Pharmacogenomics and Personalized Medicine, July 2018, Dove Medical Press

    Prof. dr. Anton J Loonen, Svetlana A Ivanova, Anastasia Levchenko, Prof Nikolay A. Bokhan

  65. Terug naar de basis: een andere focus bij neuro-psycho-biologisch onderzoek

    Article • Neuropraxis, July 2018, Springer Science + Business Media

    Prof. dr. Anton J Loonen

  66. Dried Blood Spot Analysis for Therapeutic Drug Monitoring of Clozapine

    Article • The Journal of Clinical Psychiatry, December 2017, Physicians Postgraduate Press, Inc

    Prof Nikolay A. Bokhan, Prof. dr. Anton J Loonen, Svetlana A Ivanova

  67. Commentary on “A non-reward attractor theory of depression”: A proposal to include the habenula connection

    Article • Neuroscience & Biobehavioral Reviews, December 2017, Elsevier

    Prof. dr. Anton J Loonen, Svetlana A Ivanova

  68. How brain mechanism of feeling pleasure and happiness evolved during the last 560 million years.

    Article • CNS Spectrums, November 2017, Cambridge University Press

    Prof. dr. Anton J Loonen, Svetlana A Ivanova

  69. Association between P-glycoprotein polymorphisms and antipsychotic drug-induced hyperprolactinemia

    Article • European Neuropsychopharmacology, October 2017, Elsevier

    Prof. dr. Anton J Loonen, Prof Nikolay A. Bokhan

  70. Dopamine receptors genes polymorphisms in Parkinson patients with levodopa-induced dyskinesia

    Article • European Neuropsychopharmacology, October 2017, Elsevier

    Prof. dr. Anton J Loonen

  71. Potential biomarkers of tardive dyskinesia: a multiplex analysis of blood serum

    Article • European Neuropsychopharmacology, October 2017, Elsevier

    Prof. dr. Anton J Loonen, Prof Nikolay A. Bokhan

  72. Predictive genetic model for levodopa-induced dyskinesia in patients with Parkinson’s disease

    Article • European Neuropsychopharmacology, October 2017, Elsevier

    Prof. dr. Anton J Loonen

  73. The role of the habenula in the transition from reward to misery in substance use and mood disorders

    Article • Neuroscience & Biobehavioral Reviews, September 2017, Elsevier

    Prof. dr. Anton J Loonen, Svetlana A Ivanova

  74. Circuits regulating pleasure and happiness: evolution and role in mental disorders

    Article • Acta Neuropsychiatrica, May 2017, Cambridge University Press

    Prof. dr. Anton J Loonen, Svetlana A Ivanova

  75. Prolactin gene polymorphism (− 1149 G/T) is associated with hyperprolactinemia in patients with schizophrenia treated with antipsychotics

    Article • Schizophrenia Research, April 2017, Elsevier

    Prof Nikolay A. Bokhan, Prof. dr. Anton J Loonen, Svetlana A Ivanova

  76. Association Between Prolactin Gene Polymorphism (–1149 G/T) and Hyperprolactinemia in Anti-psychotic Treated Patients with Schizophrenia

    Article • European Psychiatry, April 2017, Cambridge University Press

    Prof. dr. Anton J Loonen, Prof Nikolay A. Bokhan

  77. Biomarkers of depressive disorders: A multiplex analysis of blood serum

    Article • European Psychiatry, April 2017, Cambridge University Press

    Prof. dr. Anton J Loonen, Prof Nikolay A. Bokhan

  78. Association of Polymorphisms of Serotonin Transporter (5HTTLPR) and 5-HT2C Receptor Genes with Criminal Behavior in Russian Criminal Offenders

    Article • Neuropsychobiology, January 2017, Karger Publishers

    Prof Nikolay A. Bokhan, Prof. dr. Anton J Loonen, Svetlana A Ivanova

  79. Circuits Regulating Pleasure and Happiness in Bipolar Disorder

    Article • Frontiers in Neural Circuits, January 2017, Frontiers

    Prof. dr. Anton J Loonen, Svetlana A Ivanova

  80. Association of СОМТ gene polymorphisms with Parkinson’s disease

    Article • Bulletin of Siberian Medicine, January 2017, Siberian State Medical University

    Prof. dr. Anton J Loonen, Prof Nikolay A. Bokhan

  81. Detoxification with titration and tapering in gamma-hydroxybutyrate (GHB) dependent patients: The Dutch GHB monitor project

    Article • Drug and Alcohol Dependence, January 2017, Elsevier

    Prof. dr. Anton J Loonen

  82. Circuits Regulating Pleasure and Happiness in Schizophrenia: The Neurobiological Mechanism of Delusions

    Article • December 2016, IntechOpen

    Prof. dr. Anton J Loonen, Svetlana A Ivanova

  83. Likelihood of mechanistic roles for dopaminergic, serotonergic and glutamatergic receptors in tardive dyskinesia: A comparison of genetic variants in two independent patient populations

    Article • SAGE Open Medicine, November 2016, SAGE Publications

    Prof. dr. Anton J Loonen, Prof Nikolay A. Bokhan, Svetlana A Ivanova

  84. Circuits Regulating Pleasure and Happiness: The Evolution of the Amygdalar-Hippocampal-Habenular Connectivity in Vertebrates

    Article • Frontiers in Neuroscience, November 2016, Frontiers

    Prof. dr. Anton J Loonen, Svetlana A Ivanova

  85. Circuits Regulating Pleasure and Happiness—Mechanisms of Depression

    Article • Frontiers in Human Neuroscience, November 2016, Frontiers

    Prof. dr. Anton J Loonen, Svetlana A Ivanova

  86. Gene polymorphism of neurotransmitter transporters in schizophrenic patients with drug-induced hyperprolactinemia

    Article • European Neuropsychopharmacology, October 2016, Elsevier

    Prof. dr. Anton J Loonen, Prof Nikolay A. Bokhan

  87. Gene polymorphism of serotonin receptors and drug-induced hyperprolactinemia in schizophrenic patients

    Article • European Neuropsychopharmacology, October 2016, Elsevier

    Prof. dr. Anton J Loonen, Prof Nikolay A. Bokhan

  88. Identification of 5-hydroxytryptamine receptor gene polymorphisms modulating hyperprolactinaemia in antipsychotic drug-treated patients with schizophrenia

    Article • The World Journal of Biological Psychiatry, September 2016, Taylor & Francis

    Prof Nikolay A. Bokhan, Prof. dr. Anton J Loonen, Svetlana A Ivanova

  89. Comments on Lucire and Crotty, 2011

    Article • Pharmacogenomics and Personalized Medicine, August 2016, Dove Medical Press

    Prof. dr. Anton J Loonen

  90. The Effect of Co-occurring Substance Use on Gamma-hydroxybutyric Acid Withdrawal Syndrome

    Article • Journal of Addiction Medicine, July 2016, Wolters Kluwer Health

    Prof. dr. Anton J Loonen

  91. Circuits regulating pleasure and happiness in major depression

    Article • Medical Hypotheses, February 2016, Elsevier

    Prof. dr. Anton J Loonen, Svetlana A Ivanova

  92. The Neurobiological Mechanisms of Gamma-Hydroxybutyrate Dependence and Withdrawal and Their Clinical Relevance: A Review

    Article • Neuropsychobiology, January 2016, Karger Publishers

    Prof. dr. Anton J Loonen

  93. Levodopa-Induced Dyskinesia Is Related to Indirect Pathway Medium Spiny Neuron Excitotoxicity: A Hypothesis Based on an Unexpected Finding

    Article • Parkinson s Disease, January 2016, Hindawi Publishing Corporation

    Prof. dr. Anton J Loonen, Svetlana A Ivanova

  94. Circuits regulating pleasure and happiness: the evolution of reward-seeking and misery-fleeing behavioral mechanisms in vertebrates

    Article • Frontiers in Neuroscience, October 2015, Frontiers

    Prof. dr. Anton J Loonen, Svetlana A Ivanova

  95. P.5.d.005 Polymorphisms of DRD2, DRD3, DRD4 and HTR2C genes in levodopa-induced dyskinesias in Parkinson's disease

    Article • European Neuropsychopharmacology, September 2015, Elsevier

    Prof. dr. Anton J Loonen, Prof Nikolay A. Bokhan

  96. Baclofen as Relapse Prevention in the Treatment of Gamma-Hydroxybutyrate Dependence

    Article • Journal of Clinical Psychopharmacology, June 2015, Wolters Kluwer Health

    Prof. dr. Anton J Loonen

  97. New Studies On Clozapine Treatment in Psychosis

    Article • European Psychiatry, March 2015, Cambridge University Press

    Prof. dr. Anton J Loonen

  98. Cytochrome P450 1A2 co-determines neuroleptic load and may diminish tardive dyskinesia by increased inducibility

    Article • The World Journal of Biological Psychiatry, January 2015, Taylor & Francis

    Prof Nikolay A. Bokhan, Prof. dr. Anton J Loonen, Svetlana A Ivanova

  99. Association Study Indicates a Protective Role of Phosphatidylinositol-4-Phosphate-5-Kinase against Tardive Dyskinesia

    Article • The International Journal of Neuropsychopharmacology, December 2014, Oxford University Press (OUP)

    Prof Nikolay A. Bokhan, Prof. dr. Anton J Loonen, Svetlana A Ivanova

  100. Practical recommendations for improvement of the physical health care of patients with severe mental illness

    Article • Acta Psychiatrica Scandinavica, December 2014, Wiley

    Prof. dr. Anton J Loonen

  101. Evaluation of health promotion programmes in severe mental illness: theory and practice

    Article • International Journal of Methods in Psychiatric Research, December 2014, Wiley

    Prof. dr. Anton J Loonen

  102. Poster #S267 IMPROVING SOMATIC HEALTH OF OUTPATIENTS WITH SEVERE MENTAL ILLNESS

    Article • Schizophrenia Research, April 2014, Elsevier

    Prof. dr. Anton J Loonen

  103. Dehydroepiandrosterone sulphate as a putative protective factor against tardive dyskinesia

    Article • Progress in Neuro-Psychopharmacology and Biological Psychiatry, April 2014, Elsevier

    Prof. dr. Anton J Loonen, Prof Nikolay A. Bokhan, Svetlana A Ivanova

  104. EPA-0301 – Improving somatic health of outpatients with severe mental illness

    Article • European Psychiatry, January 2014, Cambridge University Press

    Prof. dr. Anton J Loonen

  105. No news without new scientific ideas

    Article • CNS Spectrums, December 2013, Cambridge University Press

    Prof. dr. Anton J Loonen

  106. Reply

    Article • Acta Psychiatrica Scandinavica, December 2013, Wiley

    Prof. dr. Anton J Loonen

  107. Improvement of care for the physical health of patients with severe mental illness: a qualitative study assessing the view of patients and families

    Article • BMC Health Services Research, October 2013, Springer Science + Business Media

    Prof. dr. Anton J Loonen

  108. Is Somatic Health Screening in Patients With Severe Mental Illness of Added Value?

    Article • Perspectives In Psychiatric Care, September 2013, Hindawi Publishing Corporation

    Prof. dr. Anton J Loonen

  109. Evaluating interventions to improve somatic health in severe mental illness: a systematic review

    Article • Acta Psychiatrica Scandinavica, February 2013, Wiley

    Prof. dr. Anton J Loonen

  110. New insights into the mechanism of drug-induced dyskinesia

    Article • CNS Spectrums, December 2012, Cambridge University Press

    Prof. dr. Anton J Loonen, Svetlana A Ivanova

  111. Are immediate‐ and extended‐release drugs interchangeable?

    Article • Acta Psychiatrica Scandinavica, November 2012, Wiley

    Prof. dr. Anton J Loonen

  112. Influencing CYP Enzymes to Boost Psychiatric Treatment: A Review on Clinical Evidence

    Article • Pharmacopsychiatry, October 2012, Thieme Publishing Group

    Prof. dr. Anton J Loonen

  113. Little hope for further innovations in psychopharmacology?

    Article • Human Psychopharmacology Clinical and Experimental, September 2012, Wiley

    Prof. dr. Anton J Loonen

  114. Gaps in health care for the somatic health of outpatients with severe mental illness

    Article • International Journal of Mental Health Nursing, July 2012, Wiley

    Prof. dr. Anton J Loonen

  115. Abstracts from the 28th CINP World Congress of Neuropsychopharmacology, Stockholm, Sweden, 3–7 June 2012

    Article • The International Journal of Neuropsychopharmacology, May 2012, Oxford University Press (OUP)

    Prof. dr. Anton J Loonen

  116. No involvement of the adenosine A2A receptor in tardive dyskinesia in Russian psychiatric inpatients from Siberia

    Article • Human Psychopharmacology Clinical and Experimental, May 2012, Wiley

    Prof. dr. Anton J Loonen, Svetlana A Ivanova

  117. NMDA receptor genotypes associated with the vulnerability to develop dyskinesia

    Article • Translational Psychiatry, January 2012, Springer Science + Business Media

    Prof. dr. Anton J Loonen, Svetlana A Ivanova

  118. Behandeling met medicatie

    Article • January 2012, Springer Science + Business Media

    Prof. dr. Anton J Loonen

  119. Substantial skin disorders in psychiatric illness coincide with diabetes and addiction

    Article • Journal of the European Academy of Dermatology and Venereology, March 2011, Wiley

    Prof. dr. Anton J Loonen

  120. Reply

    Article • Acta Psychiatrica Scandinavica, January 2011, Wiley

    Prof. dr. Anton J Loonen

  121. The Mechanism of Drug-induced Akathisia

    Article • CNS Spectrums, January 2011, Cambridge University Press

    Prof. dr. Anton J Loonen

  122. Risk Factors for Overweight and Diabetes mellitus in Residential Psychiatric Patients

    Article • Obesity Facts, January 2011, Karger Publishers

    Prof. dr. Anton J Loonen

  123. Treatment adherence therapy in people with psychotic disorders: randomised controlled trial

    Article • The British Journal of Psychiatry, December 2010, Royal College of Psychiatrists

    Prof. dr. Anton J Loonen

  124. Functional psychopharmacology is the way to go in pharmacotherapy for psychiatric disorders

    Article • Acta Psychiatrica Scandinavica, November 2010, Wiley

    Prof. dr. Anton J Loonen

  125. Skin disorders in chronic psychiatric illness

    Article • Journal of the European Academy of Dermatology and Venereology, September 2010, Wiley

    Prof. dr. Anton J Loonen

  126. Missense polymorphisms in three oxidative-stress enzymes (GSTP1, SOD2, and GPX1) and dyskinesias in Russian psychiatric inpatients from Siberia

    Article • Human Psychopharmacology Clinical and Experimental, January 2010, Wiley

    Prof. dr. Anton J Loonen, Prof Nikolay A. Bokhan, Svetlana A Ivanova

  127. Tardive dyskinesia and DRD3, HTR2A and HTR2C gene polymorphisms in Russian psychiatric inpatients from Siberia

    Article • Progress in Neuro-Psychopharmacology and Biological Psychiatry, April 2009, Elsevier

    Prof. dr. Anton J Loonen, Prof Nikolay A. Bokhan, Svetlana A Ivanova

  128. Evidence That Patients With Single Versus Recurrent Depressive Episodes Are Differentially Sensitive to Treatment Discontinuation

    Article • The Journal of Clinical Psychiatry, September 2008, Physicians Postgraduate Press, Inc

    Prof. dr. Anton J Loonen

  129. Visualizing Pharmacological Activities of Antidepressants: A Novel Approach

    Article • The Open Pharmacology Journal, June 2008, Bentham Science Publishers

    Prof. dr. Anton J Loonen

  130. A cross-sectional study of prescribing patterns in chronic psychiatric patients living in sheltered housing facilities

    Article • International Journal of Clinical Pharmacology and Therapeutics, March 2008, Dustri-Verlgag Dr. Karl Feistle

    Prof. dr. Anton J Loonen

  131. Measuring Movement Disorders in Antipsychotic Drug Trials

    Article • Journal of Clinical Psychopharmacology, October 2007, Wolters Kluwer Health

    Prof. dr. Anton J Loonen

  132. Adding and Switching Antipsychotics

    Article • Psychiatric Services, October 2007, American Psychiatric Association

    Prof. dr. Anton J Loonen

  133. P.2.g.006 Effectiveness of a combination of Hypericum and Passiflora for the treatment of depression with concomitant anxiety

    Article • European Neuropsychopharmacology, October 2007, Elsevier

    Prof. dr. Anton J Loonen

  134. P.2.b.001 Treatment with electroconvulsive therapy is associated with an increase of nitric oxide synthesis

    Article • European Neuropsychopharmacology, October 2007, Elsevier

    Prof. dr. Anton J Loonen

  135. Letter

    Article • Psychiatric Services, October 2007, American Psychiatric Association

    Prof. dr. Anton J Loonen

  136. Hypothermia following antipsychotic drug use

    Article • European Journal of Clinical Pharmacology, March 2007, Springer Science + Business Media

    Prof. dr. Anton J Loonen

  137. Treatment with ect is associated with an increase of nitric oxide

    Article • European Psychiatry, March 2007, Cambridge University Press

    Prof. dr. Anton J Loonen

  138. Understanding and Improving Treatment Adherence in Patients with Psychotic Disorders: A Review and a Proposed Intervention

    Article • Current Psychiatry Reviews, November 2006, Bentham Science Publishers

    Prof. dr. Anton J Loonen

  139. Aripiprazole in chronic schizophrenia: experiences in daily practice

    Article • Acta Psychiatrica Scandinavica, July 2006, Wiley

    Prof. dr. Anton J Loonen

  140. Neurobiologie van cognitieve en emotionele motivatie

    Article • Neuropraxis, June 2006, Springer Science + Business Media

    Prof. dr. Anton J Loonen

  141. 3 Biologische therapievormen

    Article • January 2006, Springer Science + Business Media

    Prof. dr. Anton J Loonen

  142. Bipolar mania and plasma amino acids: Increased levels of glycine

    Article • European Neuropsychopharmacology, January 2006, Elsevier

    Prof. dr. Anton J Loonen

  143. Nitric Oxide and Neopterin in Bipolar Affective Disorder

    Article • Neuropsychobiology, January 2006, Karger Publishers

    Prof. dr. Anton J Loonen

  144. Seksuele motivatie: meer dan dopaminerge stimulatie van het ventrale striatum

    Article • Neuropraxis, December 2005, Springer Science + Business Media

    Prof. dr. Anton J Loonen

  145. Dyspepsia in Chronic Psychiatric Patients

    Article • Pharmacopsychiatry, May 2005, Thieme Publishing Group

    Prof. dr. Anton J Loonen

  146. Oral risperidone with lorazepam versus oral zuclopenthixol with lorazepam in the treatment of acute psychosis in emergency psychiatry: a prospective, comparative, open-label study

    Article • Journal of Psychopharmacology, January 2005, SAGE Publications

    Prof. dr. Anton J Loonen

  147. Indeling en bijwerkingen van psychofarmaca

    Article • Neuropraxis, December 2004, Springer Science + Business Media

    Prof. dr. Anton J Loonen

  148. Cardiovascular Risk Factors in Outpatients with Bipolar Disorder

    Article • Pharmacopsychiatry, September 2004, Thieme Publishing Group

    Prof. dr. Anton J Loonen

  149. Delirium in elderly hospitalised patients: protective effects of chronic rivastigmine usage

    Article • International Journal of Geriatric Psychiatry, June 2004, Wiley

    Prof. dr. Anton J Loonen

  150. Retrospective evaluation of the effect of omeprazole on clozapine metabolism

    Article • Pharmacy World & Science, June 2004, Springer Science + Business Media

    Prof. dr. Anton J Loonen

  151. Responsivity to Stress in Chronic Posttraumatic Stress Disorder Due to Childhood Sexual Abuse

    Article • Psychological Reports, April 2004, SAGE Publications

    Prof. dr. Anton J Loonen

  152. P.2.035 Risperidone versus zuclopentixol in acute psychosis in emergency psychiatry: A prospective naturalistic study

    Article • European Neuropsychopharmacology, October 2003, Elsevier

    Prof. dr. Anton J Loonen

  153. P.2.083 Pilot study of the effects of rivastigmine in schizophrenia

    Article • European Neuropsychopharmacology, October 2003, Elsevier

    Prof. dr. Anton J Loonen

  154. The influence of zinc on the uptake of vitamin B12 by the cerebrospinal fluid

    Article • International Journal of Geriatric Psychiatry, May 2003, Wiley

    Prof. dr. Anton J Loonen

  155. Outcomes and costs of treatment with risperidone in adult and elderly patients: the Delta patient using risperidone study

    Article • Progress in Neuro-Psychopharmacology and Biological Psychiatry, December 2002, Elsevier

    Prof. dr. Anton J Loonen

  156. Dyspepsia in chronic psychiatric patients

    Article • European Neuropsychopharmacology, October 2002, Elsevier

    Prof. dr. Anton J Loonen

  157. The Schedule for the Assessment of Drug-Induced Movement Disorders (SADIMoD): inter-rater reliability and construct validity

    Article • The International Journal of Neuropsychopharmacology, December 2001, Oxford University Press (OUP)

    Prof. dr. Anton J Loonen

  158. Side effects of psychiatric-medication in a large population of chronically admitted psychiatric patients

    Article • European Neuropsychopharmacology, January 2001, Elsevier

    Prof. dr. Anton J Loonen

  159. Concurrent validity and sensitivity to change of the SADIMoD

    Article • European Neuropsychopharmacology, January 2001, Elsevier

    Prof. dr. Anton J Loonen

  160. The Schedule for the Assessment of Drug-Induced Movement Disorders (SADIMoD): test–retest reliability and concurrent validity

    Article • The International Journal of Neuropsychopharmacology, December 2000, Oxford University Press (OUP)

    Prof. dr. Anton J Loonen

  161. Comparison of indications and treatment outcomes of risperidone in elderly and younger patients

    Article • European Neuropsychopharmacology, September 2000, Elsevier

    Prof. dr. Anton J Loonen

  162. Test-retest reliability and concurrent validity of the SADIMoD

    Article • European Neuropsychopharmacology, September 2000, Elsevier

    Prof. dr. Anton J Loonen

  163. Cardiovascular risk factors and lithium in bipolar disorder

    Article • European Neuropsychopharmacology, September 2000, Elsevier

    Prof. dr. Anton J Loonen

  164. Interrater reliability and construct validity of the SADIMoD

    Article • European Neuropsychopharmacology, September 2000, Elsevier

    Prof. dr. Anton J Loonen

  165. Neuroendocrinological, biochemical and psychophysiological characteristics of chronic posttraumatic stress disorder

    Article • European Neuropsychopharmacology, September 2000, Elsevier

    Prof. dr. Anton J Loonen

  166. Lack of drug interactions between mirtazapine and risperidone in psychiatric patients: a pilot study

    Article • European Neuropsychopharmacology, December 1999, Elsevier

    Prof. dr. Anton J Loonen

  167. Concomitant use of mirtazapine and risperidone: A pilot study

    Article • European Neuropsychopharmacology, September 1999, Elsevier

    Prof. dr. Anton J Loonen

  168. Effect of blood collection tubes on tricyclic antidepressant blood levels

    Article • European Neuropsychopharmacology, November 1998, Elsevier

    Prof. dr. Anton J Loonen

  169. Figure copying in patients with schizophrenia: Relationship between negative symptoms and the complexity of figures

    Article • Schizophrenia Research, January 1998, Elsevier

    Prof. dr. Anton J Loonen

  170. P.2.034 Tremor in schizophrenic patients treated with antipsychotics

    Article • European Neuropsychopharmacology, September 1997, Elsevier

    Prof. dr. Anton J Loonen

  171. Article • Pharmacy World & Science, January 1997, Springer Science + Business Media

    Prof. dr. Anton J Loonen

  172. Psychomotor slowing in depression and schizophrenia

    Article • European Neuropsychopharmacology, June 1996, Elsevier

    Prof. dr. Anton J Loonen

  173. Influence of Heparin on the Assay of Amitriptyline, Clomipramine, and Their Metabolites

    Article • Therapeutic Drug Monitoring, June 1996, Wolters Kluwer Health

    Prof. dr. Anton J Loonen

  174. Dealing with sadness, madness and hostility

    Article • August 1992

    Prof. dr. Anton J Loonen

  175. A Comparison of Carbamazepine Divitabs and a Normal Carbamazepine Preparation in Psychiatric and Oligophrenic Patients

    Article • Pharmacopsychiatry, May 1992, Thieme Publishing Group

    Prof. dr. Anton J Loonen

  176. Is Diltiazem Effective in Treating the Symptems of (Tardive) Dyskinesia in Chronic Psychiatric Inpatients? A Negative, Double-Blind, Placebo-Controlled Trial

    Article • Current Opinion in Cardiology, February 1992, Wolters Kluwer Health

    Prof. dr. Anton J Loonen

  177. Is Diltiazem Effective in Treating the Symptoms of (Tardive) Dyskinesia in Chronic Psychiatric Inpatients? A Negative, Double-Blind, Placebo-Controlled Trial

    Article • Journal of Clinical Psychopharmacology, February 1992, Wolters Kluwer Health

    Prof. dr. Anton J Loonen

  178. Continuation and maintenance therapy with antidepressive agents

    Article • August 1991

    Prof. dr. Anton J Loonen

  179. Continuation and maintenance therapy with antidepressive agents

    Article • August 1990

    Prof. dr. Anton J Loonen

  180. A comparison of carbamazepine divitabs with carbamazepine normal formulation in psychiatric and oligophrenic patients

    Article • February 1989

    Prof. dr. Anton J Loonen

  181. Halopemide, a new psychotropic agent

    Article • February 1985

    Prof. dr. Anton J Loonen

  182. Receptorinteracties in vivo en in vitro

    Article • December 1981

    Prof. dr. Anton J Loonen

  183. Effects of halopemide on GABA receptor binding, uptake and release

    Article • Brain Research, April 1981, Elsevier

    Prof. dr. Anton J Loonen

  184. Ceratoniapitten bij uremie

    Article • December 1980

    Prof. dr. Anton J Loonen

  185. Chenodesoxycholzuur, een tumor-promotor?

    Article • December 1980

    Prof. dr. Anton J Loonen

  186. Boekbesprekingen

    Article • Pharmaceutisch Weekblad, December 1979, Springer Science + Business Media

    Prof. dr. Anton J Loonen

  187. Boekbesprekingen

    Article • Pharmaceutisch Weekblad, December 1979, Springer Science + Business Media

    Prof. dr. Anton J Loonen

  188. Referaten

    Article • December 1979

    Prof. dr. Anton J Loonen

  189. The regional localization of R28935 in the cat brain as dependent on the route of administration

    Article • Naunyn-Schmiedeberg s Archives of Pharmacology, November 1979, Springer Science + Business Media

    Prof. dr. Anton J Loonen

  190. Regional distribution of halopemide, a new psychotropic agent, in the rat brain at different time intervals and after chronic administration

    Article • Life Sciences, February 1979, Elsevier

    Prof. dr. Anton J Loonen

  191. Regional localization of halopemide, a new psychotropic agent, in the rat brain

    Article • European Journal of Pharmacology, August 1978, Elsevier

    Prof. dr. Anton J Loonen

  192. The regional localisation of a new potent centrally acting antihypertensive agent R 28935 and its less active threo-isomer R 29814 in the cat brain

    Article • European Journal of Pharmacology, October 1977, Elsevier

    Prof. dr. Anton J Loonen